[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
Dr. Ronan Foley, MD, is a Co-Founder of Glafabra and a transplant specialist.
With co-founder Dr. Jeffrey Medin, he co-led the Canadian FACTS trial (NCT02800070), which followed five Fabry patients for five years, including the non-myeloablative, melphalan-based conditioning that allowed 4 of 5 patients to go home the same day.
For diligence purposes: the clinician who led the pilot study's transplant and conditioning work is a co-founder of the company taking the approach forward.
See the Sep 16 post for why the outpatient conditioning approach matters.
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Chris Hopkins @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0